Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

40.70 -1.37 (-3.26%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗

March 25, 2025

The company is working on a non-stimulant approach to treating ADHD.

Via Investor's Business Daily

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

March 21, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) appears to be flying under the radar despite its strong fundamentals. ↗

March 15, 2025

SUPERNUS PHARMACEUTICALS INC may be an undervalued stock option. NASDAQ:SUPN retains a strong financial foundation and an attractive price tag.

Via Chartmill

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

March 14, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Small-Cap Stocks Skating on Thin Ice

March 13, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Supernus to Participate in Two Upcoming Investor Conferences

March 04, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

March 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

February 27, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.

Via StockStory

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

Viatris Earnings: What To Look For From VTRS

February 26, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect.

Via StockStory

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

February 26, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

February 25, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the...

Via StockStory

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

February 24, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know.

Via StockStory

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

February 19, 2025

Via Benzinga

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial ↗

February 19, 2025

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on its future.

Via Benzinga

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 19, 2025

Via Benzinga

Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

February 19, 2025

Via Benzinga

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

February 18, 2025

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

February 18, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

February 11, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

February 04, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

January 27, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗

January 06, 2025

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

Via Talk Markets

Topics ETFs Stocks / Equities

Screening For Black Friday Bargains In The Stock Market ↗

December 03, 2024

Via Benzinga

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

November 26, 2024

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.